Navigation Links
Bioniche Pharma Launches Ibutilide Fumarate Injection
Date:1/12/2010

LAKE FOREST, Ill., Jan. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert® from Pfizer Inc.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma will supply Ibutilide Fumarate Injection in 0.1 mg/mL, 10mL vials.

This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please refer to the Bioniche Pharma website at www.bionichepharma.com for the complete prescribing information for this product, including the boxed warning.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in
'/>"/>

SOURCE Bioniche Pharma
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
2. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
3. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
(Date:5/23/2013)... 23, 2013   BioLife Solutions , Inc. (OTC:BLFS), ... grade hypothermic storage and cryopreservation freeze ... aseptic media manufacturer , today announced its participation at ... Congress 2013 this week in London ... Dr. Aby J. Mathew, BioLife,s Senior Vice President ...
(Date:5/23/2013)... PARIS , May 23, 2013 /PRNewswire/ ... developer and manufacturer of precision guided therapy tools designed ... peripheral vascular disease, today announced preliminary results from the ... ndependent S tenosis E valuation) II trial ... at EuroPCR 2013. These prospective results confirm prior retrospective ...
Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5
... CAMBRIDGE, Mass. , Feb. 4 Recognizing that ... information they contain, Northern Light ( www.northernlight.com ) today announced ... in excess of $2 billion can be searched, ... has been steadily increasing the number of market research sources ...
... , CARLSBAD, Calif. , Feb. 4 Genoptix, Inc. ... that it expects to report its financial results for the fourth quarter ... Thursday, February 25, 2010 . , A conference call hosted ... members of senior management will take place on the same day at ...
Cached Medicine Technology:Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 2Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 3Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 3
(Date:5/23/2013)... Clinic researchers have used next generation genomic analysis to ... tumors have similar genetic origins, which may help in ... the journal Cancer Research . , "This is ... generation sequencing in adjacent Gleason patterns in the same ... pathology," says ,John Cheville, M.D., Mayo Clinic pathologist and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Dr. Katherine ... new charitable organization in Orange County, OCCares , will ... Orange County. The event details are as follows: , ... Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , ... crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
(Date:5/23/2013)... New York, NY (PRWEB) May 23, 2013 ... http://bit.ly/Z4m6UI , Canadian tech start-ups are increasingly seeing ... deals with larger US-based companies, according to ... business development engine. , The company has compiled ... entitled Borderless Investments. The findings of the research have ...
(Date:5/23/2013)... 23, 2013 Cheap Concert Tickets announces that ... of 2013 at stadiums throughout North America. This well ... Paul McCartney concert tickets to help McCartney fans see Sir ... Concert Tickets, states that she is also offering the customer ... Being a baby boomer, she is also a huge ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- Symptoms of ... psychiatric disorders, complicating diagnosis and treatment. But researchers ... that may be unique to borderline personality disorder: ... face. , , "They have difficulty processing facial ... a neutral face," said Anthony Ruocco, a clinical ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3
... Jan. 30 A report issued today by ... consultancy,based in Washington, D.C., confirms that Blue Cross ... to the people of Michigan in 2007 through,an ... improve access to,health coverage at affordable prices. The ...
... A new study of age-related macular degeneration (AMD), a disease ... way for the biopharmaceutical industry to develop better treatments and ... the research. , This is the first time that ... that closely represents the disease in people, said Stephen Rose, ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) announced ... 40 mg (Pantoprazole Sodium,DR), which is AB-rated to ... Industries, Ltd. (Sun Pharma). Sun Pharma recently received,approval ... for its Abbreviated,New Drug Application (ANDA) for generic ...
... Mass., Jan. 30 Weston Medical Publishing ... of Disaster Medicine,( http://www.disastermedicinejournal.com ), sister publication ... ), has been accepted for,inclusion into the ... may,now be accessed through the PUBMED website ...
... chain attempted to silence union activist, CHICAGO, Jan. ... (NLRB) has issued an unfair labor practice complaint,against Resurrection ... at West Suburban Medical Center, an RHC-affiliated hospital. The,NLRB ... told a union,activist that he could no longer speak ...
... DELRAY BEACH, Fla., Jan. 30 More than 100 ... 25 at Diagnostic,Centers of America (DCA) Delray Beach medical ... cardiac and diagnostic,medical imaging, enabling physicians to obtain clearer ... to beat and without the need for beta blockers., ...
Cached Medicine News:Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 3Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 2Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 3Health News:American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicine's MEDLINE Database and may now be Accessed Through the PUBMED Website or the MEDLARS System 2Health News:Labor Board Issues Complaint Against Resurrection Health Care 2Health News:Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with World's Most Advanced Cardiac Scanner. 2
... The Pediatric BladderScan® ... to Diagnostic Ultrasound's trusted ... By enabling healthcare providers ... bladder volume noninvasively, this ...
... Bladder Monitor is a handheld, noninvasive ... provider to enable patients to monitor ... It is easy to use and ... patient can make informed decisions about ...
... The BladderScan BVM 6500 ... noninvasively to determine UEBW ... and bladder volume using ... BVM 6500 was designed ...
... Implant, the world's leading bulking therapy, is ... treatment of Stress Urinary Incontinence (SUI). Natural ... tissue to aid coaptation in a defective ... structure, Contigen Bard Collagen Implant forms a ...
Medicine Products: